Diana Akhmedova

Ms. Diana Akhmedova

Institute of pharmaceutical technologies
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2023 in Sciences of Pharmacy
Verified
Journal Article
Open access
PDF file
IIIvan S. Ivanov
Ivan S. Ivanov
DADiana Akhmedova
Diana Akhmedova
YKYulia Anatolyevna Koroleva
Yulia Anatolyevna Koroleva
DSDenis O. Shatalov
Denis O. Shatalov
Preservatives in eye drops, while not always necessary, can lead to undesirable effects. Developing preservative-free solutions demands special measures for sterility, utilizing multidose or monodose primary packaging. This review explores the merits and drawbacks of these packaging types. A literature search on PubMed, Google Scholar, and EMBASE until December 2023, using MESH terms, yielded 28 studies on multidose ampoules and 24 on monodose packaging. Heterogeneous data revealed advantages and disadvantages concerning patient use and manufacturing. Chronologically presenting the development of eye drop packaging, this study finds Droptainer® simple but unable to maintain sterility. Comod®, 3K®, ABAK®, Novelia®, and Ophthalmic Squeeze Dispenser show high sterility probability, with Comod® and ABAK® having a contamination risk. Novelia® excels with long-term sterility and better control. Ophthalmic Squeeze Dispenser, FDA-approved, boasts a smaller carbon footprint. Unit-dose systems preserve sterility and offer design flexibility. Proposing an alternative, blister technology maintains sterility, is convenient and safe, and holds promise for recycling. This comprehensive assessment aids in understanding the evolving landscape of eye drop packaging, emphasizing the importance of sterility, convenience, and environmental impact.

7 September 2022 in International Journal of Applied Pharmaceutics
Verified
Journal Article
Open access
PDF file
IIIvan S. Ivanov
Ivan S. Ivanov
EBElena Bakhrushina
Elena Bakhrushina
ATAnastasia Romanovna Turaeva
Anastasia Romanovna Turaeva
DSDenis O. Shatalov
Denis O. Shatalov
AAAnna Viktorovna Aydakova
Anna Viktorovna Aydakova
SKStanislav Anatol’eVich Kedik
Stanislav Anatol’eVich Kedik
The purpose of this study is to find a unique ophthalmic packaging that takes into account modern requirements for both maintaining the quality and safety of the drug, compliance with therapy, and increasing the profitability and environmental friendliness of its production. Statistics from open international databases on drugs approved for ophthalmic therapy in 2022 are provided. The research criteria were a valid registration status, the type of packaging and the presence of a preservative in the composition of the eye drops. The results of statistical processing of databases of ministries of health of different countries have shown the relevance of monodose ophthalmic packaging, capable of long-term storage of the drug without preservatives. In many countries, particularly in Europe, many drugs in the form of a monodose containers are registered. On this basis, a unique aluminum-based monodose container design is proposed, eliminating the use of large quantities of plastic.

29 September 2021 in Fine Chemical Technologies
Verified
Journal Article
Open access
PDF file
DADiana Akhmedova
Diana Akhmedova
DSDenis O. Shatalov
Denis O. Shatalov
IIIvan S. Ivanov
Ivan S. Ivanov
AAA. V. Aydakova
A. V. Aydakova
AHA. Herbst
A. Herbst
SKS. A. Kedik
S. A. Kedik
Objectives. To develop a method for the microfluidic synthesis of oligohexamethylene guanidine salts in a flow-type reactor and to evaluate its effectiveness in relation to the synthesis in a traditional capacitive reactor and compare the purities of products obtained by these methods.Methods. The synthesis of oligohexamethylene guanidine bihydrocarbonate (OHMG-BHC) was done using microfluidic hardware and the classical approach in volume. The purity and structure of the resulting product were confirmed by 13C NMR spectroscopy and high-performance liquid chromatography (HPLC).Results. The 13C NMR spectrum of OHMG-BHC in classical bulk synthesis demonstrates that the product is unbranched and contains additionally unidentifiable impurities, in contrast to the sample obtained by the microfluidic method. Furthermore, the HPLC analysis showed that the OHMG-BHC sample synthesized using microfluidic technology has a 1.5-fold lower content than the initial monomers.Conclusions. The advantage of synthesizing OHMG-BHC in a flow-type reactor compared to the traditional method of synthesis in volume is demonstrated since a product with a higher degree of purity is obtained.

7 June 2021 in Molecules
Verified
Journal Article
Open access
PDF file
DSDenis O. Shatalov
Denis O. Shatalov
SKStanislav A. Kedik
Stanislav A. Kedik
IIIvan S. Ivanov
Ivan S. Ivanov
AAAnna V. Aydakova
Anna V. Aydakova
DADiana Akhmedova
Diana Akhmedova
VVViktor Volok
Viktor Volok
This paper reports the synthesis of branched alkylene guanidines using microfluidic technologies. We describe the preparation of guanidine derivatives at lower temperatures, and with significantly less time than that required in the previously applicable method. Furthermore, the use of microfluidics allows the attainment of high-purity products with a low residual monomer content, which can expand the range of applications of this class of compounds. For all the samples obtained, the molecular-weight characteristics are calculated, based on which the optimal condensation conditions are established. Additionally, in this work, the antiviral activity of the alkylene guanidine salt against the SARS-CoV-2 virus is confirmed.

29 May 2021 in Drug development & registration
Verified
Journal Article
Open access
PDF file
YDYu. M. Domnina
Yu. M. Domnina
VSV. V. Suslov
V. V. Suslov
SKS. A. Kedik
S. A. Kedik
DADiana Akhmedova
Diana Akhmedova
AMA. P. Malkova
A. P. Malkova
Introduction. Acute toxicity of naltrexone hydrochloride nasal spray during intragastric administration to mice and local irritant effect on rabbits was studied. At all stages of the experiment, observations were made on the General condition of the animals. The state of homeostasis was evaluated using functional, hematological and morphometric methods. According to the results of research, there was no local irritant effect on the eyes of rabbits, as well as no toxic effect of high doses of the drug on animals. Introduction. Naltrexone hydrochloride in doses of 1.5– 5 mg/day has shown its effectiveness in the treatment of a number of diseases. Due to the lack of such a "low-dose" naltrexone registered on the pharmaceutical market, we have developed the composition of the nasal spray naltrexone hydrochloride. One of the stages of our research is to study the safety of the drug being developed. The first step in this direction was to study its acute toxicity and local irritant effect.Aim. Study of acute toxicity and local irritant effect of naltrexone hydrochloride nasal spray.Materials and methods. The object of the study was a nasal spray of naltrexone hydrochloride. Acute toxicity studies were performed on outbred adult mice (females). Study of local irritant effect on Soviet chinchilla rabbits (males).Results and discussion. The study of acute toxicity showed that the drug, at a dose significantly higher than the estimated maximum daily therapeutic dose for humans, did not have a significant toxic effect on the body of laboratory animals. The presence of a local irritant effect in the studied drug was not established in the framework of the experiment.Conclusion. As part of the experiment, the drug under study did not have a local irritant or toxic effect on the animal body. The results obtained allow us to continue the development and study of the nasal spray naltrexone hydrochloride.

2 November 2021 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
SBSergei V. Beliakov
Sergei V. Beliakov
DSDenis O. Shatalov
Denis O. Shatalov
VAV. N. Aldobaev
V. N. Aldobaev
IIIvan S. Ivanov
Ivan S. Ivanov
AAA. V. Aydakova
A. V. Aydakova
SKS. A. Kedik
S. A. Kedik
Branched oligohexamethyleneguanidine hydrochloride (branched OHMG-HC) possesses high biocidal activity. This study aimed at evaluating the pharmacokinetics of branched OHMG-HC and is mandatory for obtaining permission to conduct clinical studies. The thermal activation method was used to obtain radioactive-labeled drugs for the investigation of substance distribution in various tissues of experimental animals (rats and rabbits). Substance administration was carried out both orally (a dose was split into two equal volumes that were applied to buccal zones of the oral cavities of the animals) and intravenously to get a clear pharmacokinetic profile. In this research, the drug was applied in the concentration of 0.77 mg/kg with the addition of 0.037 mg/kg 3H-OHMG for rats, and 0.42 mg/kg with the addition of 0.015 mg/kg 3H-OHMG for Chinchilla rabbits. The selected samples of blood, organs and urine underwent alkaline mineralization. A quantitative determination of 3H-OHMG was carried out using a liquid β-, γ-counter according to the level of scintillation in the sample. Branched OHMG-HC displayed uniform distribution within all main organs and tissues upon oral administration. The highest concentrations were found in liver and kidney tissues, whereas the lowest in blood, cardiac muscle tissue and brain. The closeness of the fabs values obtained from different animals (24.5% for rats and 29.0% for rabbits) demonstrated the absence of the species specificity in response to the pharmaceutical substance. The main parameters of excretion were established, and the half-life time was estimated to be 15 hours.